[1]
Wu ZL, Miao XL, Jiang YC, et al. Cardiomyocytic cGAS is critical for induction of experimental cardiac graft rejection. Journal of Thoracic and Cardiovascular Surgery (accepted) (*corresponding author)
[2]
Miao XL, Wu ZL, Jiang YC, Liu H. An efficient combination immunotherapy for antitumor immunity without accelerating cardiac allograft rejection. Immunology 2022 Dec 14; Online ahead of print (*corresponding author)
[http://dx.doi.org/10.1111/imm.13618]
[http://dx.doi.org/10.1111/imm.13618]
[3]
Kong DQ, Huang SY, Miao XL, et al. The dynamic cellular landscape of grafts with acute rejection after heart transplantation. J Heart Lung Transplant 2023 Feb; 42(2): 160-72. Epub 2022 Nov 2. (*corresponding author)
[http://dx.doi.org/10.1016/j.healun.2022.10.017]
[http://dx.doi.org/10.1016/j.healun.2022.10.017]
[4]
Miao XL, Jiang YC, Kong DQ, Wu ZL, Liu H, Ye XL. Lactobacillus rhamnosus HN001 ameliorates BEZ235-induced intestinal dysbiosis and prolongs cardiac transplant survival. Microbiology Spectrum 2022 Aug 31; 10(4): e0079422. Epub 2022 Jul 11 (*corresponding author)
[http://dx.doi.org/10.1128/spectrum.00794-22]
[http://dx.doi.org/10.1128/spectrum.00794-22]
[5]
Luan FM. Gastric metastasis after tibial sarcoma surgery. Am J Gastroenterol 2022 Oct 1; 117(10): 1556. Epub 2022 Jun 2. (*corresponding author)
[http://dx.doi.org/10.14309/ajg.0000000000001845]
[http://dx.doi.org/10.14309/ajg.0000000000001845]
[6]
Li XQ, Li SP, Wu B, et al. Landscape of Immune Cells Heterogeneity in Liver Transplantation by Single-Cell RNA Sequencing Analysis. Front Immunol 2022 May 10; eCollection 2022. (*corresponding author)
[http://dx.doi.org/10.3389/fimmu.2022.890019.]
[http://dx.doi.org/10.3389/fimmu.2022.890019.]
[7]
Jiang YC, Kong DQ, Miao XL, Yu X, Wu ZL, Liu H. Anti-cytokine therapy and small molecule agents for the treatment of inflammatory bowel disease. Eur Cytokine Netw 2021 Dec 1; 32(4): 73-82. (*corresponding author)
[8]
Wang Y, Miao XL, Jiang YC, et al. The synergistic antitumor effect of IL-6 neutralization with NVP-BEZ235 in hepatocellular carcinoma. Cell Death Dis 2022 Feb 14; 13(2): 146. (*corresponding author)
[http://dx.doi.org/10.1038/s41419-022-04583-5]
[http://dx.doi.org/10.1038/s41419-022-04583-5]
[9]
Kong D, Jiang Y, Miao X, Wu Z, Liu H. Tadalafil enhances the therapeutic efficacy of BET inhibitors in hepatocellular carcinoma through activating Hippo pathway. Biochim Biophys Acta Mol Basis Dis 2021 Dec 1; 1867(12): 166267. Epub 2021 Sep 9 (*corresponding author)
[http://dx.doi.org/10.1016/j.bbadis.2021.166267]
[http://dx.doi.org/10.1016/j.bbadis.2021.166267]
[10]
Miao X, Liu C, Jiang Y, et al. BET protein inhibition evidently enhances sensitivity to PI3K/mTOR dual inhibition in intrahepatic cholangiocarcinoma. Cell Death Dis 2021 Oct 29; 12(11): 1020. (*corresponding author)
[http://dx.doi.org/10.1038/s41419-021-04305-3]
[http://dx.doi.org/10.1038/s41419-021-04305-3]
